154 related articles for article (PubMed ID: 24067137)
21. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia.
Goemans BF; Zwaan CM; Miller M; Zimmermann M; Harlow A; Meshinchi S; Loonen AH; Hählen K; Reinhardt D; Creutzig U; Kaspers GJ; Heinrich MC
Leukemia; 2005 Sep; 19(9):1536-42. PubMed ID: 16015387
[TBL] [Abstract][Full Text] [Related]
22. FMS-like tyrosine kinase 3 (FLT3) modulates key enzymes of nucleotide metabolism implicated in cytarabine responsiveness in pediatric acute leukemia.
Perelló-Reus CM; Català A; Caviedes-Cárdenas L; Vega-García N; Camós M; Pérez-Torras S; Pastor-Anglada M
Pharmacol Res; 2020 Jan; 151():104556. PubMed ID: 31778791
[TBL] [Abstract][Full Text] [Related]
23. Frequency of FLT3 mutations in childhood acute lymphoblastic leukemia.
Braoudaki M; Karpusas M; Katsibardi K; Papathanassiou Ch; Karamolegou K; Tzortzatou-Stathopoulou F
Med Oncol; 2009 Dec; 26(4):460-2. PubMed ID: 19085113
[TBL] [Abstract][Full Text] [Related]
24. Cooperation of MLL/AF10(OM-LZ) with PTPN11 activating mutation induced monocytic leukemia with a shorter latency in a mouse bone marrow transplantation model.
Fu JF; Liang ST; Huang YJ; Liang KH; Yen TH; Liang DC; Shih LY
Int J Cancer; 2017 Mar; 140(5):1159-1172. PubMed ID: 27859216
[TBL] [Abstract][Full Text] [Related]
25. Molecular Characterization of Pediatric Acute Myeloid Leukemia: Results of a Multicentric Study in Brazil.
Andrade FG; Noronha EP; Brisson GD; Dos Santos Vicente Bueno F; Cezar IS; Terra-Granado E; Thuler LCS; Pombo-de-Oliveira MS;
Arch Med Res; 2016 Nov; 47(8):656-667. PubMed ID: 28476193
[TBL] [Abstract][Full Text] [Related]
26. Clinical relevance of FLT3 gene abnormalities in Brazilian patients with infant leukemia.
Emerenciano M; Menezes J; Vasquez ML; Zalcberg I; Thuler LC; Pombo-de-Oliveira MS;
Leuk Lymphoma; 2008 Dec; 49(12):2291-7. PubMed ID: 19052976
[TBL] [Abstract][Full Text] [Related]
27. PTPN11 mutations in childhood acute lymphoblastic leukemia occur as a secondary event associated with high hyperdiploidy.
Molteni CG; Te Kronnie G; Bicciato S; Villa T; Tartaglia M; Basso G; Biondi A; Cazzaniga G
Leukemia; 2010 Jan; 24(1):232-5. PubMed ID: 19776760
[No Abstract] [Full Text] [Related]
28. FLT3 mutations in a 10 year consecutive series of 177 childhood acute leukemias and their impact on global gene expression patterns.
Andersson A; Paulsson K; Lilljebjörn H; Lassen C; Strömbeck B; Heldrup J; Behrendtz M; Johansson B; Fioretos T
Genes Chromosomes Cancer; 2008 Jan; 47(1):64-70. PubMed ID: 17943971
[TBL] [Abstract][Full Text] [Related]
29. Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.
Yoshida N; Yagasaki H; Xu Y; Matsuda K; Yoshimi A; Takahashi Y; Hama A; Nishio N; Muramatsu H; Watanabe N; Matsumoto K; Kato K; Ueyama J; Inada H; Goto H; Yabe M; Kudo K; Mimaya J; Kikuchi A; Manabe A; Koike K; Kojima S
Pediatr Res; 2009 Mar; 65(3):334-40. PubMed ID: 19047918
[TBL] [Abstract][Full Text] [Related]
30. Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome.
Marková J; Marková J; Trnková Z; Michková P; Maaloufová J; Starý J; Cetkovský P; Schwarz J
Leuk Lymphoma; 2009 Sep; 50(9):1448-60. PubMed ID: 19603346
[TBL] [Abstract][Full Text] [Related]
31. Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study.
Shimada A; Iijima-Yamashita Y; Tawa A; Tomizawa D; Yamada M; Norio S; Watanabe T; Taga T; Iwamoto S; Terui K; Moritake H; Kinoshita A; Takahashi H; Nakayama H; Koh K; Goto H; Kosaka Y; Saito AM; Kiyokawa N; Horibe K; Hara Y; Oki K; Hayashi Y; Tanaka S; Adachi S
Int J Hematol; 2018 May; 107(5):586-595. PubMed ID: 29330746
[TBL] [Abstract][Full Text] [Related]
32. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes.
Badar T; Patel KP; Thompson PA; DiNardo C; Takahashi K; Cabrero M; Borthakur G; Cortes J; Konopleva M; Kadia T; Bohannan Z; Pierce S; Jabbour EJ; Ravandi F; Daver N; Luthra R; Kantarjian H; Garcia-Manero G
Leuk Res; 2015 Dec; 39(12):1367-74. PubMed ID: 26547258
[TBL] [Abstract][Full Text] [Related]
33. The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia.
Allen C; Hills RK; Lamb K; Evans C; Tinsley S; Sellar R; O'Brien M; Yin JL; Burnett AK; Linch DC; Gale RE
Leukemia; 2013 Sep; 27(9):1891-901. PubMed ID: 23783394
[TBL] [Abstract][Full Text] [Related]
34. Genetic mutational analysis of pediatric acute lymphoblastic leukemia from a single center in China using exon sequencing.
Zhang H; Wang H; Qian X; Gao S; Xia J; Liu J; Cheng Y; Man J; Zhai X
BMC Cancer; 2020 Mar; 20(1):211. PubMed ID: 32164600
[TBL] [Abstract][Full Text] [Related]
35. Genetic mutational profiling analysis of T cell acute lymphoblastic leukemia reveal mutant FBXW7 as a prognostic indicator for inferior survival.
Yuan L; Lu L; Yang Y; Sun H; Chen X; Huang Y; Wang X; Zou L; Bao L
Ann Hematol; 2015 Nov; 94(11):1817-28. PubMed ID: 26341754
[TBL] [Abstract][Full Text] [Related]
36. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML).
Boissel N; Leroy H; Brethon B; Philippe N; de Botton S; Auvrignon A; Raffoux E; Leblanc T; Thomas X; Hermine O; Quesnel B; Baruchel A; Leverger G; Dombret H; Preudhomme C; ;
Leukemia; 2006 Jun; 20(6):965-70. PubMed ID: 16598313
[TBL] [Abstract][Full Text] [Related]
37. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition.
Irving J; Matheson E; Minto L; Blair H; Case M; Halsey C; Swidenbank I; Ponthan F; Kirschner-Schwabe R; Groeneveld-Krentz S; Hof J; Allan J; Harrison C; Vormoor J; von Stackelberg A; Eckert C
Blood; 2014 Nov; 124(23):3420-30. PubMed ID: 25253770
[TBL] [Abstract][Full Text] [Related]
38. Acute lymphoblastic leukemia in the context of RASopathies.
Cavé H; Caye A; Strullu M; Aladjidi N; Vignal C; Ferster A; Méchinaud F; Domenech C; Pierri F; Contet A; Cacheux V; Irving J; Kratz C; Clavel J; Verloes A
Eur J Med Genet; 2016 Mar; 59(3):173-8. PubMed ID: 26855057
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia.
Kuwatsuka Y; Tomizawa D; Kihara R; Nagata Y; Shiba N; Iijima-Yamashita Y; Shimada A; Deguchi T; Miyachi H; Tawa A; Taga T; Kinoshita A; Nakayama H; Kiyokawa N; Saito AM; Koh K; Goto H; Kosaka Y; Asou N; Ohtake S; Miyawaki S; Miyazaki Y; Sakura T; Ozawa Y; Usui N; Kanamori H; Ito Y; Imai K; Suehiro Y; Kobayashi S; Kitamura K; Sakaida E; Ogawa S; Naoe T; Hayashi Y; Horibe K; Manabe A; Mizutani S; Adachi S; Kiyoi H
Int J Hematol; 2018 Feb; 107(2):201-210. PubMed ID: 29027108
[TBL] [Abstract][Full Text] [Related]
40. Clinical significance of FLT3 in leukemia.
Kiyoi H; Yanada M; Ozekia K
Int J Hematol; 2005 Aug; 82(2):85-92. PubMed ID: 16146837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
